GLP-1 & compounded medication availability in Illinois (2026)

Illinois polices compounded GLP-1s mainly through consumer-protection enforcement: the state attorney general has sent cease-and-desist letters to med-spa sellers, warned residents about products passed off as brand-name drugs, and co-led a national coalition to FDA. Here is what actually ships to Illinois addresses across all ten product lines we track, stated the way that enforcement record demands: compounded products called compounded.

Conditional state

Availability facts last reviewed: November 16, 2026

What ships to Illinois: all ten lines

Availability of all ten OrderlyMeds product lines in Illinois, with typical delivery times and notes
Product lineAvailable in Illinois?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Compounded, and labeled that way. Ships under a patient-specific prescription.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Every dose at one national price.
NAD+ Yes 8–10 business days Ships from licensed partner pharmacies.
Sermorelin Yes 8–10 business days Longevity line, standard ordering flow.
Glutathione No N/A Not offered by OrderlyMeds today.
BPC-157 Yes 8–10 business days Compounded injectable; federal record below.
TB-500 Yes 8–10 business days Compounded injectable. See below.
KPV No N/A Not carried; peptide lines ship as injectables only.
Epitalon Yes 8–10 business days Compounded injectable; the federal picture is below.
MOTS-c Yes 8–10 business days Compounded injectable; its federal record is distinct, below.

Every “No” in this table is deliberate. Illinois facts on this page were last reviewed on November 16, 2026.

Research peptides in Illinois: BPC-157, TB-500, KPV, Epitalon & MOTS-c

Four of these five ship to Illinois addresses as compounded injectables under patient-specific prescriptions: BPC-157, TB-500, Epitalon and MOTS-c. KPV does not, because our peptide lines are injectables only. Illinois’s attorney general has gone after sellers who market peptides and GLP-1s deceptively (see the regulator section below), so the sections here do the opposite: each states its substance’s own federal record, in full, whether the line ships to you or not.

BPC-157 in Illinois

Ships to Illinois addresses as a compounded injectable, filled under a patient-specific prescription and labeled as the compounded product it is. The federal facts below apply in full.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Illinois

Available to Illinois addresses as a compounded injectable under a patient-specific prescription. Its own federal record follows.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Illinois

We do not ship KPV to Illinois or anywhere else. Our peptide lines are compounded as injectables, and KPV is not one of them.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Illinois

In the Illinois formulary as a compounded injectable on a patient-specific prescription. The federal facts below are stated without varnish.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Illinois

MOTS-c ships to Illinois addresses as a compounded injectable on a patient-specific prescription. Its federal record below is its own, not the other four’s.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Illinois’s regulators say about compounded medications

Illinois is the state where scrutiny of compounded GLP-1s has come primarily from the consumer-protection side. The state attorney general has sent cease-and-desist letters to sellers who blurred the line between brand-name and compounded products, published a consumer alert, and co-led a national coalition pressing FDA to act. The pharmacy-licensing side has stayed quieter, a posture worth understanding before you buy from anyone, including us.

In December 2024, the Illinois Attorney General issued cease-and-desist letters to five Chicago-area med spas over marketing that could lead consumers to believe they were buying name-brand GLP-1 medications when the products were compounded versions, and published a consumer alert stating that compounded drugs are not generic drugs, are not FDA-approved, and are not reviewed by FDA for safety, quality or effectiveness. Source: Office of the Illinois Attorney General — consumer alert, December 2024.

On February 19, 2025, the Illinois Attorney General co-led a bipartisan coalition of state attorneys general urging FDA to act against counterfeit GLP-1 drugs in the U.S. supply chain, against online sellers offering GLP-1 active ingredients directly to consumers without prescriptions under “research use only” labels, and against any compounding pharmacies participating unlawfully in that market. Source: Office of the Illinois Attorney General — coalition letter to FDA, Feb. 19, 2025.

Illinois’s pharmacy regulator — the Department of Financial and Professional Regulation, which houses the State Board of Pharmacy — has circulated FDA’s 2024 letter about compounded drug products containing semaglutide or tirzepatide to its licensees, and has published no Illinois-specific restriction on those compounds beyond the federal framework. Source: Illinois Department of Financial and Professional Regulation — Pharmacy.

Illinois permits prescribing on the basis of a telehealth encounter that meets the state’s standard of care; no in-person-first requirement applies to the medications on this page. Source: Center for Connected Health Policy (CCHP) Policy Finder.

The attorney general’s campaign is aimed at a specific failure: sellers passing compounded products off as brand-name drugs, or shipping “research use only” powder to consumers. The honest version of this market is a real prescription from a licensed provider, a licensed pharmacy, and a label that says compounded because it is. That is precisely what those letters demand, and it is how every OrderlyMeds order to Illinois works: eligibility check, telehealth evaluation with an Illinois-licensed provider, fulfillment by a licensed partner pharmacy. Pricing is national; Illinois pays the same number on our pricing page as every other state.

Illinois availability FAQs

Is compounded semaglutide available in Illinois?

Yes. OrderlyMeds ships compounded semaglutide to Illinois addresses under a patient-specific prescription, sold as what it is, a compounded medication, which is exactly the labeling honesty the state attorney general’s enforcement letters demand. New customers start at $74/month for the first two months.

Do I need an in-person doctor visit to start in Illinois?

No. Illinois accepts a telehealth evaluation that meets the standard of care, and every OrderlyMeds evaluation is conducted by an Illinois-licensed provider.

Can I get BPC-157 or other research peptides shipped to Illinois?

BPC-157, TB-500, Epitalon and MOTS-c ship to Illinois as compounded injectables under patient-specific prescriptions. KPV does not, because we compound these lines as injectables only. Each substance’s section above carries its own federal record, FDA’s safety position included, no matter where you buy.

How long does delivery to Illinois take?

Our published window is 8–10 business days from signup to an Illinois address.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone